Hologic, Inc. (NASDANQ:HOLX), is generating massive investor interest due to various factors. The firm's expected Q3 2025 earnings are estimated at $1.09 per share, and the company is regularly exceeding market returns. Despite macro issues, the stock is gaining from new offerings, and some factors are indicating long-term value. Hologic launched the '#BustTheMyth' campaign for breast health awareness and also rang the opening bell. Hologic's Q2 earnings for 2024 beat estimates, and the company has upgraded its view for 2024. Recently, Magnetar Financial LLC and Select Equity Group L.P. made significant investments in Hologic. The firm has also completed the acquisition of Endomagnetics Ltd, signaling expansion in its domain. The financial results for the third quarter of fiscal 2024 show revenues beating expectations, but EPS lags behind. Furthermore, the company has a favorable 66% return over the last five years, appealing to investors. Yet, the stock's performance in the market is marked as underperforming. Despite this, Hologic's CEO sold shares worth more than $3.5 million.
Hologic HOLX News Analytics from Wed, 05 May 2021 07:00:00 GMT to Sat, 12 Oct 2024 12:06:56 GMT -
Rating 6
- Innovation -2
- Information 8
- Rumor 4
